NCT04690595View on ClinicalTrials.gov

BAFFR Targeting CAR-T Cells for the Treatment of Relapsed or Refractory B-cell ALL

PHASE1RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

May 18, 2021

Primary Completion Date

November 18, 2026

Study Completion Date

November 18, 2027

Conditions
Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
Interventions
BIOLOGICAL

BAFFR-CAR T cells

First-in-human trial examining the safety and preliminary efficacy of BAFFR-CAR T cells in participants with r/r B-ALL

Trial Locations (1)

91010

RECRUITING

City of Hope Medical Center, Duarte

Sponsors
All Listed Sponsors
collaborator

City of Hope Medical Center

OTHER

lead

PeproMene Bio, Inc.

INDUSTRY

NCT04690595 - BAFFR Targeting CAR-T Cells for the Treatment of Relapsed or Refractory B-cell ALL | Biotech Hunter | Biotech Hunter